Boston Children’s Hospital has been granted a patent for compounds that inhibit the membrane proximal external region (MPER) of viral envelopes, specifically targeting HIV-1 and HIV-2 infections. The patent includes methods for treating or preventing these viral infections using the agent S2C3. GlobalData’s report on Boston Children’s Hospital gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Boston Children's Hospital, was a key innovation area identified from patents. Boston Children's Hospital's grant share as of July 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Inhibiting viral envelope region to treat hiv infections
The granted patent US12064425B2 outlines a method for treating viral infections, specifically targeting human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2). The method involves administering an agent known as S2C3, which inhibits the membrane proximal external region (MPER) of the viral envelope (Env). This inhibition is crucial as it prevents the fusion of the viral envelope with the target cell, thereby impeding the infection process. The claims also specify that prior to treatment, a subject must be diagnosed with an HIV-1 or HIV-2 infection, or the results of an assay confirming such an infection must be obtained.
Additionally, the patent addresses scenarios where the HIV infection may be resistant to existing treatments. It highlights that the method can be applied to cases where the infection is resistant to at least one HIV treatment, including specific fusion inhibitors such as Maraviroc, Enfuvirtide, Sifuvirtide, or Albuvirtide. The target cells affected by the infection include leukocytes, lymphocytes, T cells, or specifically CD4+ T cells. This patent presents a targeted approach to HIV treatment, focusing on a novel mechanism of action that could potentially benefit patients with resistant strains of the virus.
To know more about GlobalData’s detailed insights on Boston Children's Hospital, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
